Zhitong Finance APP News, Chengda Pharmaceutical (301201.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters at 0.244 billion yuan, a decrease of 6.34% year-on-year. The net income attributable to shareholders of the listed company was 40.3928 million yuan, a decrease of 33.98% year-on-year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 14.4317 million yuan, a decrease of 59.78% year-on-year. The basic earnings per share was 0.2654 yuan.